We are live on ! Find out more
INDV icon

Indivior Pharmaceuticals
INDV

113 hedge funds and large institutions have $975M invested in Indivior Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 23 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 4 → 8 (+4)

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

70% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 23

17% more capital invested

Capital invested by funds: $834M → $975M (+$141M)

10% more funds holding

Funds holding: 103 → 113 (+10)

7.02% more ownership

Funds ownership: 54.97% → 62% (+7%)

2% more call options, than puts

Call options by funds: $831K | Put options by funds: $811K

Holders
113
Holders Change
+10
Holders Change %
+9.71%
% of All Funds
1.49%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
28
Increased
39
Reduced
23
Closed
16
Calls
$831K
Puts
$811K
Net Calls
+$20K
Net Calls Change
-$390K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$39M
2
Goldman Sachs
Goldman Sachs
New York
+$21.8M
3
RCMNY
Rubric Capital Management (New York)
New York
+$14M
4
WAM
Weiss Asset Management
Massachusetts
+$8.41M
5
Citigroup
Citigroup
New York
+$7.73M

Top Sellers

Rank Fund Capital Flow
1
Norges Bank
Norges Bank
Norway
-$21.6M
2
Morgan Stanley
Morgan Stanley
New York
-$17.2M
3
Barclays
Barclays
United Kingdom
-$14M
4
MP
Mangrove Partners
Connecticut
-$11.3M
5
ITP
Iron Triangle Partners
Connecticut
-$8.24M
Name Holding Trade Value Shares
Change 		Change in
Stake
VAS
26
VR Advisory Services
Cayman Islands
$8.22M – – –
Qube Research & Technologies (QRT)
27
Qube Research & Technologies (QRT)
United Kingdom
$7.3M +$3.23M +314,142 +115%
Marshall Wace
28
Marshall Wace
United Kingdom
$6.3M +$4.53M +440,072 +660%
RCMU
29
Rokos Capital Management (UK)
United Kingdom
$6.21M – – –
BFM
30
Boothbay Fund Management
New York
$5.88M +$1.87M +181,637 +66%
Citadel Advisors
31
Citadel Advisors
Florida
$5.6M +$1.42M +138,211 +44%
AFA
32
Alta Fundamental Advisers
New York
$4.97M +$772K +75,000 +23%
FC
33
Foursixthree Capital
New York
$4.64M +$3.84M +373,231 New
SCM
34
Stonepine Capital Management
Oregon
$3.79M +$360K +35,000 +13%
GJL
35
Gendell Jeffrey L
$3.77M +$3.12M +303,263 New
Deutsche Bank
36
Deutsche Bank
Germany
$3.59M +$370K +35,953 +14%
CEI
37
Clark Estates Inc
New York
$3.2M +$33.9K +3,300 +1%
PCM
38
Prelude Capital Management
New York
$3.01M +$2.5M +242,546 New
Allianz Asset Management
39
Allianz Asset Management
Germany
$2.86M -$1.95M -189,647 -46%
Swiss National Bank
40
Swiss National Bank
Switzerland
$2.78M -$56K -5,440 -2%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$2.76M -$63.8K -6,199 -3%
CSS
42
Cubist Systematic Strategies
Connecticut
$2.72M +$2.25M +218,958 New
SP
43
SIH Partners
Delaware
$2.7M +$2.23M +217,058 New
VIM
44
VELA Investment Management
Ohio
$2.26M +$578K +56,224 +46%
Amundi
45
Amundi
France
$2.11M +$196K +19,010 +12%
HS
46
HighVista Strategies
Massachusetts
$1.83M – – –
KAM
47
Kazazian Asset Management
Florida
$1.71M +$1.37M +133,183 New
SSA
48
Schonfeld Strategic Advisors
New York
$1.69M +$1.4M +135,661 New
Geode Capital Management
49
Geode Capital Management
Massachusetts
$1.6M -$34.5K -3,355 -3%
UBS AM
50
UBS AM
Illinois
$1.41M – – –
1
2
3 4 5

INDV Hedge Fund Activity: Q4 2024 in Review

113 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q4 2024, worth a combined $975M — up 17% from $834M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new INDV positions and 16 closed out — a net gain of 12 holders — while 39 added to existing stakes and 23 trimmed.

The largest buyer was Deerfield Management, adding an estimated $39M. The largest seller was Norges Bank, exiting entirely with an estimated $21.6M sold.

  • 113 institutional investors held Indivior Pharmaceuticals (INDV) as of Q4 2024, up from 103 in Q3 2024.
  • Funds reported $975M of Indivior Pharmaceuticals stock for Q4 2024, up 17% quarter-over-quarter.
  • 28 funds opened new Indivior Pharmaceuticals positions in Q4 2024 and 16 closed out, a net change of +12 holders.
  • The largest Indivior Pharmaceuticals buyer in Q4 2024 was Deerfield Management, an estimated $39M added.
  • The largest Indivior Pharmaceuticals seller in Q4 2024 was Norges Bank, an estimated $21.6M sold.

Based on aggregated 13F filings for Q4 2024.